Indian Journal of Critical Care Case Report

Register      Login

VOLUME 1 , ISSUE 1 ( July-August, 2022 ) > List of Articles


COVID-19 Associated Pulmonary Aspergillosis (CAPA) Producing Mycotic Aneurysm with Life-threatening Hemoptysis

Shailesh Rohit, Vineet Rao, Sourabh Chakraborty

Keywords : CAPA, COVID-19, Mycotic aneurysm, Posaconazole, Voriconazole

Citation Information : Rohit S, Rao V, Chakraborty S. COVID-19 Associated Pulmonary Aspergillosis (CAPA) Producing Mycotic Aneurysm with Life-threatening Hemoptysis. 2022; 1 (1):1-3.

DOI: 10.5005/jp-journals-11006-0001

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


In a post-COVID-19 patient with suspected invasive mold infection of the lung and massive hemoptysis due to mycotic aneurysms, management to tackle hemoptysis takes precedence over empiric antifungal drugs. Posaconazole and isavuconazole may indeed emerge as good contemporary choices over voriconazole for invasive aspergillosis and over amphotericin B for invasive mucormycosis. This case adds to the clinical experience of using medical treatment with posaconazole as the sole drug without surgery in cases such as these, due to certain extenuating circumstances.

PDF Share
  1. Arendrup MC, Friberg N, Mares M, et al. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect 2020;26(11):1464–1472. DOI: 10.1016/j.cmi.2020.06.007
  2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408–415. DOI: 10.1056/nejmoa020191
  3. Lamaris GA, Ben-Ami R, Lewis RE, et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009;199(9):1399–1406. DOI: 10.1086/597615
  4. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760–769. DOI: 10.1016/S0140-6736(15)01159-9
  5. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016;16(7):828–837. DOI: 10.1016/S1473-3099(16)00071-2
  6. Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021;397(10273):499–509. DOI: 10.1016/S0140-6736(21)00219-1
  7. Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother 2019;74(11):3315–3327. DOI: 10.1093/jac/dkz344
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.